Ignite Creation Date:
2024-05-05 @ 9:17 PM
Last Modification Date:
2024-10-26 @ 10:02 AM
Study NCT ID:
NCT00852670
Status:
COMPLETED
Last Update Posted:
2009-11-13
First Post:
2009-02-26
Brief Title:
ACT-128800 in Psoriasis
Sponsor:
Actelion
Organization:
Actelion
Study Overview
Official Title:
Multicenter Randomized Double-blind Placebo-controlled Phase IIa Study to Evaluate the Efficacy Safety and Tolerability of ACT-128800 an S1P1 Receptor Agonist Administered for 6 Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status:
COMPLETED
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the efficacy safety and tolerability of ACT-128800 in subjects with moderate to severe plaque psoriasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None